Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis

Transplant Infectious Disease

Volumn 17, Issue 2, 2015, Pages 163-173

  Stevens, D R ^a   Sawinski, D ^b   Blumberg, E ^b   Galanakis, N ^c   Bloom, R D ^b   Trofe Clark, J ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Infection; Prophylaxis; Renal transplant; Valganciclovir

Indexed keywords

AZATHIOPRINE; GANCICLOVIR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ABNORMAL LABORATORY RESULT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OPPORTUNISTIC INFECTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SURVIVAL RATE; TREATMENT DURATION; VIRUS RESISTANCE; ALLOGRAFT; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CYTOMEGALOVIRUS INFECTIONS; DOSE RESPONSE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VIROLOGY;

ACADEMIC MEDICAL CENTERS; ADULT; ALLOGRAFTS; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925362776     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12349     Document Type: Article

References (36)

1. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14 (6): 633-641.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
3. Razonable R. Direct and indirect effects of cytomegalovirus: can we prevent them? Enferm Infecc Microbiol Clin 2010; 28: 1-5.
4. Helantera I, Lautenschlager I, Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int 2011; 24: 1170-1178.
5. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
6. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965-981.
7. Stratta RJ, Pietrangeli C, Baillie GM. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation. Pharmacotherapy 2010; 30 (2): 144-157.
8. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 93-106.
9. Hodson EM, Ladhani M, Webster AC, Strippoli GFM, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2: CD003774.
10. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731-735.
11. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36: 3107-3112.
12. Manuel O, Venetz JP, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly 2007; 137: 669-676.
13. Weng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83: 290-296.
14. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007; 83: 874-882.
15. Avidan YP, Paul M, Rahamimov R, et al. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect 2008; 57: 236-240.
16. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323-1330.
17. Luan FL, Stuckey LJ, Park JM, et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449-2458.
18. Bhat V, McIntyre M, Meyers T. Efficacy and safety of a lower-dose valganciclovir regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients. P T 2010; 35 (12): 676-679.
19. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011; 52 (3): 313-321.
20. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5): 1228-1237.
21. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008; 8 (6): 1287-1302.
22. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 (9230): 645-649.
23. Manuel O, Pascual M, Perrottet N, et al. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clin Transplant 2010; 24 (6): 794-800.
24. Genzyme Corporation. Thymoglobulin® (Rabbit Anti-Thymocyte Globulin) Package Insert. Cambridge, MA: Genzyme, 2007.
25. Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing: an opinion of the nephrology practice and research network of the American College of Clinical Pharmacy. Pharmacotherapy 2011; 31 (11): 1130-1144.
26. Humar A, Michaels M; AST ID working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring, and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 (2): 262-274.
27. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8 (4): 753-760.
28. Salas MP, Taber DJ, Chua E, et al. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis 2013; 15 (6): 551-558.
29. Maldonado AQ, Bitterman AN, Ojogho ON, Bowen KA, Weeks DL. Efficacy of valganciclovir plus cytomegalovirus immune globulin for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Ann Pharmacother 2014; 48 (4): 548-549.
30. Limaye AP, Blumberg E, Mu Y, et al. Evaluation of the modification of diet in renal disease (MDRD) equation versus the Cockcroft-Gault (CG) equation as a measure of renal function for valganciclovir dose calculations. Poster presented at 2011 ATC; April 30-May 4, 2011; Philadelphia, PA.
31. Trevillyan J, Angus P, Shelton E, et al. Electronic estimations of renal functions are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. Antimicrob Agents Chemother 2013; 57 (8): 4058-4060.
32. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4): 611-620.
33. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
34. Said T, Nampoory MR, Pacsa AS, et al. Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. Transplant Proc 2007; 39: 997-999.
35. Parreira L, Bruges M, Gaspar A, Weigert A, Machado D. Prevention of cytomegalovirus disease in renal transplantation: single-center experience. Transplant Proc 2009; 41: 877-879.
36. Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011; 11: 1936-1942.